Açıklama

Additional outcome data from the sodium butyrate trial in pediatric IBD present secondary endpoints or safety parameters monitored during the study.

Figure 7

Chart

Source Paper

Sodium Butyrate Effectiveness in Children and Adolescents with Newly Diagnosed Inflammatory Bowel Diseases-Randomized Placebo-Controlled Multicenter Trial.

Nutrients (2022)

PMID: 36014789

DOI: 10.3390/nu14163283

Cite This Figure

![Figure 7: Additional outcome data from the sodium butyrate trial in pediatric IBD present secondary endpoints or safety parameters monitored during the study.]()

> Source: Anna Pietrzak et al. "Sodium Butyrate Effectiveness in Children and Adolescents with Newly Diagnosed I." *Nutrients*, 2022. PMID: [36014789](https://pubmed.ncbi.nlm.nih.gov/36014789/)

<figure>
  <img src="" alt="Additional outcome data from the sodium butyrate trial in pediatric IBD present secondary endpoints or safety parameters monitored during the study." />
  <figcaption>Figure 7. Additional outcome data from the sodium butyrate trial in pediatric IBD present secondary endpoints or safety parameters monitored during the study.<br>  Source: Anna Pietrzak et al. "Sodium Butyrate Effectiveness in Children and Adolescents with Newly Diagnosed I." <em>Nutrients</em>, 2022. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/36014789/">36014789</a></figcaption>
</figure>

İlgili Kanıtlar

Butyrate (Sodium/Calcium Butyrate) için Ulcerative Colitis (UC)

Derece C · 3 çalışma

Butyrate (Sodium/Calcium Butyrate) için Crohn's Disease

Derece C · 2 çalışma